≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions

DOID EFO PheWeb R13 (public) Endpoint Browser PheWeb

N14_DRUGSANDHEAVYMETAL

acute kidney tubular necrosis: Acute renal failure caused by the cell death of the renal tubules. Causes include nephrotoxins, cytotoxic drugs, and antibiotics.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — N14
  • Cause of death: ICD-10 — N14

2 out of 7 registries used, show all original rules.

111

4. Check minimum number of events

None

111

5. Include endpoints

None

111

6. Filter based on genotype QC (FinnGen only)

106

Control definitions (FinnGen only)

Control exclude
N14_RENALTUB

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
N10-N16
Name in latin
Condiciones tubulo-interstitiales et tubulares ex medicamentis et metallis gravibus

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 684 289 389
Only index persons 549 241 308
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 64.13 65.48 62.95
Only index persons 62.02 64.29 60.25

-FinnGen-

Key figures

All Female Male
Number of individuals 106 44 62
Unadjusted period prevalence (%) 0.02 0.02 0.03
Median age at first event (years) 60.32 62.43 58.82

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
111
Matched controls
1110
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N14.1
ICD-10 Finland
Nephropathy induced by other drugs, medicaments and biological substances
+∞
80.2
67
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
165.9
53.7
53
6
N17.9
ICD-10 Finland
Acute renal failure, unspecified
602.8
42.1
39
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
22.9
41.9
34
21
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
10.6
31.0
44
65
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
+∞
27.2
25
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
35.4
25.8
33
13
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
+∞
22.7
21
*
N19
ICD-10 Finland
Unspecified kidney failure
39.0
21.8
27
9
TK800
NOMESCO Finland
Hemodialysis
135.7
21.4
22
*
N14.2
ICD-10 Finland
Nephropathy induced by unspecified drug, medicament or biological substance
+∞
20.4
19
*
Z49.1
ICD-10 Finland
Extracorporeal dialysis
+∞
20.4
19
*
A11CC03
ATC
alfacalcidol; systemic
+∞
18.2
17
*
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
+∞
18.2
17
*
N14.0
ICD-10 Finland
Analgesic nephropathy
+∞
17.1
16
*
N18.8
ICD-10 Finland
Other chronic renal failure
70.8
16.3
18
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
6.6
14.8
28
54
B03XA02
ATC
darbepoetin alfa; parenteral
49.7
14.6
17
*
L04AA06
ATC
mycophenolic acid; systemic
61.6
14.2
16
*
N05AN01
ATC
lithium; oral
25.1
13.9
19
9
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
7.6
13.9
22
35
N18.0
ICD-10 Finland
End-stage renal disease
+∞
13.8
13
*
N11.8
ICD-10 Finland
Other chronic tubulo-interstitial nephritis
+∞
13.8
13
*
C03CA01
ATC
furosemide; systemic
4.4
13.5
57
215
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.0
13.5
28
59
N03AG01
ATC
valproic acid; systemic, rectal
7.4
13.0
21
34
KA1AE
NOMESCO Finland
Kidney ultrasound examination
36.9
13.0
16
5
127
Kela drug reimbursment
Transplant complication
79.2
12.9
14
*
Z49.0
ICD-10 Finland
Preparatory care for dialysis
+∞
12.7
12
*
N18.5
ICD-10 Finland
Chronic kidney disease, stage 5
+∞
12.7
12
*
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
145.8
12.7
13
*
A12AA04
ATC
calcium carbonate; oral
145.8
12.7
13
*
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
52.9
12.2
14
*
JN4AD
NOMESCO Finland
Body CT examination
5.2
11.7
29
71
L04AX01
ATC
azathioprine; systemic
16.2
11.4
18
13
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.1
11.1
77
397
Z94.0
ICD-10 Finland
Kidney transplant status
+∞
10.6
10
*
V03AE01
ATC
polystyrene sulfonate; oral
+∞
10.6
10
*
N05CD07
ATC
temazepam; oral
4.8
10.4
28
73
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.3
10.1
23
52
L04AA01
ATC
[U] ciclosporin
60.4
9.8
11
*
205
Kela drug reimbursment
Chronic hypertension
3.6
9.8
47
187
N06AB04
ATC
citalopram; systemic
3.9
9.6
38
132
N17.8
ICD-10 Finland
Other acute renal failure
+∞
9.5
9
*
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
9.5
9
*
N17.0
ICD-10 Finland
Acute renal failure with tubular necrosis
+∞
9.5
9
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.0
9.4
34
111
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
8.5
9.2
20
28
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
10.0
9.2
18
21
M04AA01
ATC
allopurinol; systemic
4.1
9.1
30
91
N05AA02
ATC
levomepromazine; systemic
12.2
9.1
16
15
R50.9
ICD-10 Finland
Fever, unspecified
4.0
8.8
31
99
N05AH03
ATC
olanzapine; systemic
5.6
8.7
18
37
L04AD01
ATC
ciclosporin; systemic
22.2
8.7
12
6
H02AB04
ATC
methylprednisolone; systemic
3.9
8.5
30
96
ZXE10
NOMESCO Finland
More than one and less than three hours
3.2
8.4
56
267
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
+∞
8.4
8
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.3
8.3
46
197
A41.9
ICD-10 Finland
Sepsis, unspecified
14.5
8.1
13
10
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
14.5
8.1
13
10
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.1
8.1
55
265
ZXE00
NOMESCO Finland
One hour or less
3.1
8.0
59
297
3AC01, ,
NOMESCO Finland
48.5
7.8
9
*
R33
ICD-10 Finland
Retention of urine
4.9
7.8
19
45
J01MA02
ATC
ciprofloxacin; systemic
3.1
7.8
56
276
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
12.1
7.5
13
12
N18.4
ICD-10 Finland
Chronic kidney disease, stage 4
85.6
7.5
8
*
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
+∞
7.4
7
*
N11.9
ICD-10 Finland
Chronic tubulo-interstitial nephritis, unspecified
+∞
7.4
7
*
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
+∞
7.4
7
*
B03XA03
ATC
methoxy polyethylene glycol-epoetin beta; parenteral
+∞
7.4
7
*
F31.7
ICD-10 Finland
Bipolar affective disorder, currently in remission
18.1
6.9
10
6
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
4.1
6.8
21
60
R4190
NOMESCO Finland
Nutritional therapy
9.6
6.8
13
15
JN3AD
NOMESCO Finland
Abdominal CT examination
4.0
6.7
21
61
L04AD02
ATC
tacrolimus; systemic
73.9
6.5
7
*
F25.0
ICD-10 Finland
Schizoaffective disorder, manic type
73.9
6.5
7
*
208
Kela drug reimbursment
Ulcerative colitis and Crohn's disease
10.2
6.5
12
13
K51.5
ICD-10 Finland
Left sided colitis
12.0
6.5
11
10
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.0
6.4
15
24
Z2446
NOMESCO Finland
Social worker
4.6
6.3
16
39
F31.30
ICD-10 Finland
Bipolar disorder Depressive episode without somatic syndrome
28.5
6.3
8
*
N05CF01
ATC
zopiclone; oral
2.8
6.3
50
254
N14.4
ICD-10 Finland
Toxic nephropathy, not elsewhere classified
+∞
6.3
6
*
N25.1
ICD-10 Finland
Nephrogenic diabetes insipidus
+∞
6.3
6
*
PBM10
NOMESCO Finland
Closure of arteriovenous fistula of radial artery
+∞
6.3
6
*
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
+∞
6.3
6
*
PBU84
NOMESCO Finland
Plastic repair of arteriovenous fistula from artery of upper extremity
+∞
6.3
6
*
A03FA01
ATC
metoclopramide; systemic, rectal
3.1
6.3
33
134
N05AX12
ATC
aripiprazole; systemic
9.5
6.2
12
14
K51.9
ICD-10 Finland
Ulcerative colitis, unspecified
10.9
6.2
11
11
ZXD10
NOMESCO Finland
Scheduled procedure
2.7
6.0
53
283

TimeCodeWAS

↥

TimeCodeWAS is a tool for exploring time-dependent associations between an endpoint and health codes (diagnoses, lab tests, procedures, etc.).

The TimeCodeWAS analysis is done in three steps:

  1. Build a matched case-control set for this endpoint. Each case is matched to 5–10 controls on sex and year of birth, and controls must be at risk at the same age as the case's age of onset. TimeCodeWAS allows for controls to be reused.
  2. Count cases and controls. For each health code, and for each time window: tally the counts into a 2×2 table. To be eligible in a time window, a case or control must have data coverage for at least 50% of that time window.
  3. Perform association tests. If all cells of the 2×2 table have N≥10, then a χ² test is performed, otherwise a Fisher's exact test is done. The corresponding p-value and confidence interval are reported below, along with the standard odds ratio when a χ² test is done, or Fisher's MLE odds ratio otherwise.

TimeCodeWAS currently uses the same default set of time windows for all the endpoints. Please reach out to us if you have suggestions for better time windows for some endpoints. The default time windows are: TimeCodeWAS time windows

Sort & Filter
Sort
Odds Ratio
among windows:
Filter
Code & OMOP
Cases and controls with code
in
Odds Ratio
in
OMOP Concept
Code (OMOP Vocabulary) [OMOP Concept ID]
OMOP Concept Class / OMOP Domain
Odds Ratio
TimeCodeWAS O.R. time legend
Cases and controls with code
TimeCodeWAS Cases and Controls percentages time legend
Pharmacy visit
OMOP4822462 (Visit) [581458]
Visit / Visit
1.0e+50 — 1.3e+00 1.3e+00 1.4e+00 — 1.0e+50
100.00%/92.70% —/— 75.68%/45.14% 9.01%/2.61% 75.70%/43.10% —/— 100.00%/94.37%
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 (LOINC) [3021347]
Lab Test / Measurement
1.2e+00 1.7e+00 3.9e+00 — — 2.1e+00 1.4e+00
15.32%/5.41% 18.92%/4.05% 18.02%/0.45% —/— —/— 21.00%/3.14% 23.81%/7.22%
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 (LOINC) [3016431]
Lab Test / Measurement
1.1e+00 1.7e+00 3.9e+00 1.0e+50 — 2.1e+00 1.0e+00
16.22%/6.13% 20.72%/4.50% 20.72%/0.54% 4.50%/0.00% —/— 23.00%/3.60% 21.43%/9.13%
Phosphate [Moles/volume] in Serum or Plasma
14879-1 (LOINC) [3003458]
Lab Test / Measurement
2.5e+00 3.6e+00 1.0e+50 — — 3.4e+00 2.7e+00
8.11%/0.72% 14.41%/0.45% 15.32%/0.00% —/— —/— 17.00%/0.65% 15.48%/1.17%
Supplier / Service Provider
OMOP5117446 (Visit) [33004]
Visit / Visit
-3.2e-01 -1.0e-01 -1.0e+50 — — — 3.5e+00
19.82%/25.32% 6.31%/6.94% 0.00%/0.72% —/— —/— —/— 20.24%/0.74%
Glucose [Moles/volume] in Serum or Plasma
14749-6 (LOINC) [3013826]
Lab Test / Measurement
7.5e-01 1.5e+00 3.4e+00 — 3.2e+00 1.2e+00 1.8e-01
14.41%/7.39% 17.12%/4.32% 11.71%/0.45% —/— 10.28%/0.45% 11.00%/3.69% 14.29%/12.21%
Inpatient Hospital
21 (CMS Place of Service) [8717]
Visit / Visit
1.0e+00 2.0e+00 3.3e+00 — 2.3e+00 1.8e+00 1.3e+00
54.05%/29.28% 43.24%/9.19% 26.13%/1.26% —/— 11.21%/1.26% 38.00%/9.60% 54.76%/24.84%
Urea [Moles/volume] in Serum or Plasma
22664-7 (LOINC) [3020779]
Lab Test / Measurement
2.7e+00 — 1.0e+50 1.0e+50 1.0e+50 — 3.3e+00
6.31%/0.45% —/— 15.32%/0.00% 5.41%/0.00% 12.15%/0.00% —/— 16.67%/0.74%
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 (LOINC) [3006140]
Lab Test / Measurement
1.0e+00 1.6e+00 3.2e+00 — 2.9e+00 1.4e+00 6.9e-01
15.32%/6.22% 14.41%/3.15% 9.91%/0.45% —/— 10.28%/0.63% 14.00%/3.79% 14.29%/7.75%

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
50
12.90
35.11
9.0
1.5
146.75
61.10
ng/l
3.09
36
45
43
78
8.37
25.04
13.4
2.2
7.35
7.40
ph
3.45
35
46
57
157
6.41
21.52
8.5
2.8
0.83
0.81
mmol/l
0.33
57
152
29
39
9.71
21.47
12.1
1.4
22.66
25.18
mmol/l
2.77
29
39
36
64
7.84
21.04
21.3
8.6
—
—
—
0
0
94
458
7.87
17.34
29.4
5.4
1.22
1.21
mmol/l
0.33
76
392
30
55
7.10
16.78
16.6
7.7
24.05
25.31
mmol/l
0.76
30
55
73
300
5.19
16.13
17.0
3.1
7.38
7.40
ph
2.96
65
205
72
315
4.66
14.11
7.5
3.0
32.86
229.78
e6/l
0.46
64
235
61
240
4.42
13.71
11.8
4.4
—
—
—
0
0
69
312
4.20
12.46
6.5
3.3
140.70
46.74
mg/l
1.13
58
205
73
359
4.02
11.34
9.0
3.5
37.63
43.93
e6/l
0.10
63
250
23
29
9.71
11.31
5.8
2.5
24.15
26.23
mmol/l
1.64
23
29
68
321
3.89
11.18
8.6
4.0
29.41
9.15
mg/mmol
1.31
57
204
68
322
3.87
11.11
10.7
5.6
—
—
—
0
0
18
15
14.05
10.80
10.1
1.3
12.18
8.03
pmol/l
0.66
18
15
58
253
3.71
10.62
5.3
2.6
—
—
—
0
0
24
55
5.29
10.40
1.5
2.2
—
—
—
0
0
57
251
3.61
10.19
4.5
2.6
399.82
347.03
umol/l
2.48
51
214
59
271
3.51
9.78
8.0
2.8
0.22
0.30
e6/l
0.24
51
197
51
223
3.38
8.99
3.5
2.1
3.15
2.88
mg/l
0.27
42
192
17
19
10.34
8.92
12.2
2.1
—
—
—
0
0
25
68
4.45
8.76
7.1
2.9
5.38
5.26
kpa
0.23
25
68
83
493
3.71
8.73
13.1
6.3
0.59
0.59
e9/l
0.01
77
428
31
100
3.91
8.65
3.4
1.7
—
—
—
0
0
83
496
3.67
8.58
13.1
6.3
0.04
0.04
e9/l
0.04
77
432
84
506
3.71
8.57
14.0
6.5
0.20
0.19
e9/l
0.21
79
448
87
538
3.85
8.47
21.3
10.0
4.23
3.80
e9/l
0.74
81
479
27
80
4.14
8.45
10.0
2.5
69.74
69.87
e9/l
0.01
19
58
18
26
8.04
8.18
14.2
1.9
7.39
7.43
ph
1.58
18
26
18
27
7.74
7.99
1.4
4.7
1.21
2.62
ratio
—
8
11
77
457
3.24
7.69
32.7
12.2
1.33
1.20
inr
1.01
72
380
54
267
2.99
7.42
2.3
1.6
15.30
22.91
nmol/l
5.23
44
213
7
0
+∞
7.37
2.7
0.0
—
—
—
0
0
76
456
3.11
7.29
13.4
6.1
59.82
57.51
%
0.88
76
438
32
121
3.31
6.91
1.2
1.4
354.29
617.89
titre
—
7
38
36
148
3.12
6.76
2.6
1.6
1268.10
1255.64
nmol/l
0.02
29
115
13
17
8.50
6.33
1.5
6.1
—
—
—
0
0
6
0
+∞
6.30
11.5
0.0
4.38
—
mmol/l
—
6
0
12
14
9.45
6.23
10.8
1.1
71.44
67.01
%
0.24
12
14
32
129
3.08
6.16
17.4
6.8
105.16
103.57
mmol/l
0.81
32
129
17
46
4.18
5.90
9.0
2.1
0.59
0.59
%
0.00
17
46
17
46
4.18
5.90
9.8
2.1
1.19
1.43
%
0.35
17
46
21
67
3.63
5.83
1.8
1.7
—
—
—
0
0
36
160
2.85
5.79
3.4
1.9
—
—
—
0
0
65
389
2.62
5.77
6.1
3.1
6.30
6.17
ph
0.43
38
213
10
10
10.84
5.66
2.4
1.4
87.40
90.41
%
—
10
10
31
134
2.82
5.20
3.8
1.5
—
—
—
0
0
12
20
6.59
5.07
13.3
1.8
8.33
8.64
kpa
0.18
12
20
12
20
6.59
5.07
13.3
1.8
5.10
4.95
kpa
0.25
12
20
25
100
2.94
4.79
16.9
7.4
7.40
7.42
ph
0.71
14
59
22
82
3.10
4.76
11.8
4.0
—
—
—
0
0
31
140
2.68
4.75
6.1
2.5
0.74
2.19
e6/l
0.77
19
66
8
8
10.65
4.60
1.5
1.4
29.50
18.20
ng/l
—
8
8
67
436
2.35
4.58
40.3
11.9
0.00
0.01
e9/l
0.47
58
357
16
50
3.57
4.54
10.6
2.5
174.63
131.96
ng/l
0.24
16
45
23
93
2.86
4.31
6.6
5.8
0.20
0.76
%
—
10
33
42
229
2.34
4.27
9.5
5.7
—
—
—
0
0
23
94
2.82
4.22
7.8
5.8
0.10
0.10
%
—
10
31
23
97
2.73
3.97
1.9
1.7
—
—
—
0
0
12
28
4.67
3.95
1.8
1.4
—
—
—
0
0
23
98
2.70
3.89
7.8
5.6
1.10
0.97
%
—
10
35
17
61
3.11
3.89
1.4
2.2
0.89
1.86
g/l
1.06
17
56
72
505
2.21
3.84
8.4
3.4
0.00
0.00
estimate
-0.00
26
121
62
411
2.15
3.81
3.0
1.9
98.76
99.76
pmol/l
0.06
37
194
8
12
7.08
3.74
2.5
1.8
—
—
—
0
0
9
16
6.02
3.74
1.3
1.3
—
—
—
0
0
16
58
3.05
3.60
22.3
10.3
0.72
0.69
%
0.14
16
58
22
96
2.61
3.55
8.1
6.5
0.00
0.41
%
—
9
32
6
6
10.47
3.54
22.7
6.0
10.02
10.52
mg/l
—
6
6
12
32
4.08
3.51
1.2
1.7
0.25
0.23
g/l
0.28
12
32
12
32
4.08
3.51
1.3
1.7
1.14
1.18
g/l
0.14
12
32
72
517
2.12
3.46
8.4
3.5
0.04
0.00
estimate
0.49
27
109
23
104
2.53
3.45
1.5
1.5
—
—
—
0
0
71
509
2.10
3.40
8.5
3.5
0.00
0.00
estimate
-0.00
27
122
16
60
2.95
3.40
22.7
10.1
1.44
1.56
%
0.18
16
60
13
46
3.07
3.03
1.0
1.2
—
—
—
0
0
33
186
2.10
2.96
2.6
1.8
465.85
417.15
pmol/l
0.43
27
155
46
296
1.95
2.85
9.1
3.5
0.00
0.03
estimate
0.50
22
111
8
19
4.45
2.73
2.4
3.5
59.75
57.65
%
—
8
19
8
19
4.45
2.73
1.5
1.7
—
—
—
0
0
45
292
1.91
2.69
14.2
5.3
—
—
—
0
0
27
146
2.12
2.68
2.4
2.0
—
—
—
0
0
23
118
2.20
2.59
1.2
1.3
—
—
—
0
0
86
695
2.05
2.58
6.3
4.3
14.82
14.85
pmol/l
0.04
81
632
18
83
2.39
2.58
1.9
1.3
—
—
—
0
0
6
11
5.69
2.58
1.0
1.1
—
—
—
0
0
6
12
5.22
2.43
1.2
1.1
—
—
—
0
0
6
12
5.22
2.43
1.2
1.1
—
—
—
0
0
6
12
5.22
2.43
1.2
1.1
—
—
—
0
0
6
12
5.22
2.43
1.2
1.1
—
—
—
0
0
21
107
2.19
2.40
1.9
1.4
—
—
—
0
0
5
8
6.48
2.39
1.0
1.4
—
—
—
0
0
12
47
2.74
2.36
6.8
4.1
36.71
36.93
°c
0.70
12
47
56
403
1.79
2.33
6.9
4.0
35.12
41.80
ng/l
0.26
43
305
6
13
4.81
2.30
2.8
3.2
4.58
4.54
e9/l
—
6
13
12
48
2.68
2.27
6.3
2.9
—
—
—
0
0
54
388
1.76
2.24
8.8
3.4
0.00
0.00
estimate
-0.00
23
103
47
326
1.77
2.19
4.0
2.3
—
—
—
0
0
5
10
5.18
2.09
2.2
1.1
9.00
11.38
%
—
5
10
12
52
2.47
1.95
4.4
3.7
3.57
4.46
pmol/l
3.20
12
45
12
54
2.37
1.81
4.0
3.5
—
—
—
0
0
30
193
1.76
1.76
1.5
1.5
2.74
2.74
g/l
0.00
24
109
59
455
1.63
1.75
4.2
2.6
—
—
estimate
—
0
0
6
19
3.28
1.68
2.0
1.6
0.85
0.98
%
—
6
12
6
19
3.28
1.68
1.8
1.6
33.17
33.21
pg
—
6
19
15
81
1.98
1.48
4.5
2.9
8.69
7.48
ug/l
0.08
15
76
7
28
2.60
1.48
5.3
4.2
4.03
3.92
mmol/l
—
7
28
5
16
3.22
1.45
1.4
1.2
—
—
—
0
0
5
17
3.03
1.37
4.8
3.0
0.76
0.75
nmol/l
—
5
17
30
207
1.62
1.34
7.5
1.5
2.18
1.25
mg/l
0.65
25
168
12
62
2.05
1.33
5.5
2.8
—
—
—
0
0
40
297
1.54
1.32
9.6
3.1
0.00
0.00
estimate
-0.00
22
102
10
49
2.14
1.26
2.0
1.3
—
—
—
0
0
10
50
2.10
1.20
1.2
1.2
—
—
—
0
0
87
771
1.59
1.19
67.1
18.5
14.19
13.60
%
3.84
87
766
5
20
2.57
1.16
1.6
1.1
—
—
—
0
0
13
75
1.83
1.08
1.5
1.9
—
—
—
0
0
14
83
1.79
1.07
2.6
1.9
0.00
0.00
estimate
—
5
19
35
265
1.47
1.02
1.7
1.4
—
—
—
0
0
6
28
2.21
0.93
1.3
1.1
561.00
488.32
mg/l
—
6
28
99
921
1.69
0.92
58.8
14.2
24.64
23.28
mg/l
0.21
93
767
45
366
1.39
0.88
2.4
2.1
—
—
—
0
0
28
214
1.41
0.77
1.5
1.2
0.84
1.68
u/ml
—
9
61
5
24
2.13
0.75
1.6
1.3
—
—
—
0
0
5
24
2.13
0.75
1.6
1.3
—
—
—
0
0
5
25
2.05
0.73
1.6
1.3
—
—
—
0
0
5
25
2.05
0.73
1.6
1.3
—
—
—
0
0
5
25
2.05
0.73
1.4
1.2
—
—
—
0
0
26
210
1.31
0.51
6.2
3.4
1.01
1.02
kg/l
1.06
21
133
5
83
0.58
0.48
1.6
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
0.26
—
0
8
0
18
0.00
0.40
0.0
1.1
—
2.17
—
0
8
0
19
0.00
0.39
0.0
1.1
—
3.21
—
0
10
15
117
1.33
0.37
1.6
1.2
—
—
—
0
0
46
417
1.18
0.31
6.0
5.2
2.23
2.71
ug/l
0.24
40
368
9
72
1.27
0.26
1.6
1.2
—
—
—
0
0
5
38
1.33
0.23
1.8
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
4.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.7
—
4.11
—
0
12
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.7
—
104.17
—
0
12
0
12
0.00
0.21
0.0
2.7
—
1.21
—
0
12
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
92
897
1.15
0.16
5.5
4.4
1.44
1.28
mmol/l
1.17
83
812
11
97
1.15
0.09
2.0
1.5
—
—
—
0
0
12
107
1.14
0.09
2.0
2.2
13.05
14.54
nmol/l
0.26
12
100
92
934
0.91
0.08
6.8
5.2
1.36
1.45
mmol/l
1.42
83
852
97
957
1.11
0.07
47.9
13.4
—
—
—
0
0
93
940
0.93
0.04
6.8
5.3
4.25
4.56
mmol/l
2.78
85
866
89
900
0.94
0.04
10.2
6.5
40.45
39.55
mmol/mol
0.30
84
849
42
429
0.97
0.02
2.8
2.0
1.48
1.37
mmol/l
0.32
34
347
94
948
0.94
0.02
7.4
6.1
2.35
2.64
mmol/l
3.28
86
870
37
378
0.97
0.02
4.1
3.4
—
—
—
0
0
18
173
1.05
0.01
1.1
1.3
22.47
31.45
iu/ml
—
6
55
16
154
1.05
0.00
1.0
1.3
8.14
11.15
u/ml
—
5
55
27
269
1.00
0.00
4.4
3.1
0.98
0.77
ug/l
0.74
20
171
91
914
0.98
0.00
7.5
5.1
6.25
5.98
mmol/l
0.96
85
834
0
5
0.00
-0.00
0.0
1.4
—
250.20
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
3.12
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
24.28
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
136.60
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
0.00
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
6.96
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint N14_DRUGSANDHEAVYMETAL and mortality.

Females

Parameter HR [95% CI] p-value
N14_DRUGSANDHEAVYMETAL 3.362 [2.25, 5.03] < 0.001
Birth year 0.996 [0.99, 1.0] 0.349

During the follow-up period (1.1.1998 — 31.12.2019), 99 out of 233 females with N14_DRUGSANDHEAVYMETAL died.

Males

Parameter HR [95% CI] p-value
N14_DRUGSANDHEAVYMETAL 3.426 [2.35, 4.99] < 0.001
Birth year 0.984 [0.97, 0.99] 0.001

During the follow-up period (1.1.1998 — 31.12.2019), 143 out of 306 males with N14_DRUGSANDHEAVYMETAL died.

Mortality risk

Mortality risk for people of age

years, who have N14_DRUGSANDHEAVYMETAL.

N-year risk Females Males
1 0.39% 0.579%
5 1.968% 3.236%
10 4.881% 8.516%
15 9.146% 16.055%
20 15.779% 26.508%

Relationships between endpoints

↥

Index endpoint: N14_DRUGSANDHEAVYMETAL – Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data